文献速递眼底病与葡萄膜炎神经眼科

司美格鲁肽的眼部不良事件:系统综述与荟萃分析

Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

该系统综述与荟萃分析纳入78项随机临床试验、共73640名成人,评估司美格鲁肽与眼部不良事件的关系。结果显示司美格鲁肽未增加或降低眼部疾病(OR 1.01;95%CI 0.91-1.12)或糖尿病视网膜病变(OR 1.04;95%CI 0.92-1.17)风险,但与NAION的比值比显著相关(OR 3.92;95%CI 1.02-15.02)。作者认为现有证据尚不足以就NAION关联得出确定性结论,需进一步研究。

要点

  • 司美格鲁肽未增加或降低眼部疾病风险(OR 1.01;95%CI 0.91-1.12)。
  • 司美格鲁肽未增加或降低糖尿病视网膜病变风险(OR 1.04;95%CI 0.92-1.17)。
  • 司美格鲁肽治疗与NAION的比值比显著相关(OR 3.92;95%CI 1.02-15.02)。

核心结论

  • 司美格鲁肽与眼部疾病或糖尿病视网膜病变风险增加无关。
  • 尽管发现司美格鲁肽治疗与NAION存在关联,现有证据仍不足以就NAION关联得出确定性结论。
  • 需要更大样本量并充分评估NAION的进一步研究来阐明这一潜在风险。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase和Cochrane对照试验中心注册库(截至2025年4月10日,无日期限制)。
  • 纳入比较司美格鲁肽与活性对照或安慰剂、评估眼部不良事件的成人随机临床试验,共78项试验、73640名参与者。
  • 采用逆方差随机效应模型汇总眼部疾病和糖尿病视网膜病变的比值比(OR),NAION采用Peto OR固定效应模型。
  • 使用RoB 2.0工具评估偏倚风险,GRADE评估证据质量,并进行试验序贯分析(TSA)。

主要发现

  • 司美格鲁肽未增加或降低眼部疾病风险(OR 1.01;95%CI 0.91-1.12)。
  • 司美格鲁肽未增加或降低糖尿病视网膜病变风险(OR 1.04;95%CI 0.92-1.17)。
  • 司美格鲁肽治疗与NAION的比值比显著相关(OR 3.92;95%CI 1.02-15.02)。
  • 总体偏倚风险低。
  • TSA提供证据表明样本量足以避免遗漏糖尿病视网膜病变的替代结果,但对NAION则不足。

关键数值与推荐

  • 主要结局包括经历眼部不良事件、糖尿病视网膜病变或NAION的患者数量。
  • 基于随访时长、对照类型和主要基线疾病进行亚组分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 现有证据仍不足以就司美格鲁肽与NAION的关联得出确定性结论。
  • TSA表明样本量对NAION不足,不足以避免遗漏替代结果。
  • 需要更大样本量并充分评估NAION的进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Semaglutide is a widely used treatment for diabetes and obesity, offering considerable cardiovascular benefit. However, its association with ocular adverse events remains uncertain. OBJECTIVE: To assess the incidence of eye disorders, diabetic retinopathy, and nonarteritic anterior ischemic optic neuropathy (NAION) in adults treated with semaglutide. DATA SOURCES: A comprehensive electronic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was conducted on April 10, 2025, without date restrictions. STUDY SELECTION: Investigators independently screened records to identify randomized clinical trials comparing semaglutide with either an active comparator or placebo in adults, assessing ocular adverse events. DATA EXTRACTION AND SYNTHESIS: Descriptive synthesis of the included studies was performed. The random-effects model using the inverse variance method was used to summarize the odds ratio (OR) for eye disorders and diabetic retinopathy. Peto OR with a fixed-effects model was applied for NAION. Risk of bias was assessed with the RoB 2.0 tool and quality of evidence with GRADE. Trial sequential analysis (TSA) was performed to determine whether the available data were sufficient for definitive conclusions. MAIN OUTCOMES AND MEASURES: The primary outcomes included the number of patients experiencing an ocular adverse event, diabetic retinopathy, or NAION. Subgroup analyses were conducted based on follow-up duration, comparator type, and primary baseline condition. RESULTS: A total of 78 trials with 73 640 participants were included. Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17). Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02). Overall risk of bias was low. TSA provided evidence that the sample size was sufficient to avoid missing alternative results for diabetic retinopathy but not for NAION. CONCLUSIONS AND RELEVANCE: These findings suggest that semaglutide was not associated with an increased risk of eye disorders or diabetic retinopathy. Despite the fact that an association between semaglutide treatment and NAION was found, current evidence remains insufficient to establish definitive conclusions regarding its association with NAION. Further studies with larger sample sizes and adequate evaluation of NAION are warranted to clarify this potential risk.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Natividade GR, Spiazzi BF, Baumgarten MW, et al. Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis. JAMA Ophthalmol. 2025. PMID: 40810985. doi:10.1001/jamaophthalmol.2025.2489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。